1. Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma☆
- Author
-
Hsiao Chi Wang, Yu-Jui Yvonne Wan, Tsung Chieh Shih, and Lijun Wang
- Subjects
0301 basic medicine ,Sorafenib ,Glypican-3 (GPC3) ,Glypican ,Hepatocellular carcinoma ,Cell ,Glypican 3 ,Article ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,medicine ,lcsh:RC799-869 ,Hepatocellular carcinoma (HCC) ,neoplasms ,Hepatology ,biology ,business.industry ,Gastroenterology ,Wnt signaling pathway ,medicine.disease ,Wnt signaling ,digestive system diseases ,030104 developmental biology ,medicine.anatomical_structure ,biology.protein ,Cancer research ,lcsh:Diseases of the digestive system. Gastroenterology ,030211 gastroenterology & hepatology ,Antibody ,business ,Glypican-3 ,medicine.drug - Abstract
Hepatocellular carcinoma (HCC) is a malignant tumor with a fairly poor prognosis (5-year survival of less than 50%). Using sorafenib, the only food and drug administration (FDA)-approved drug, HCC cannot be effectively treated; it can only be controlled at most for a couple of months. There is a great need to develop efficacious treatment against this debilitating disease. Glypican-3 (GPC3), a member of the glypican family that attaches to the cell surface by a glycosylphosphatidylinositol anchor, is overexpressed in HCC cases and is elevated in the serum of a large proportion of patients with HCC. GPC3 expression contributes to HCC growth and metastasis. Furthermore, several different types of antibodies targeting GPC3 have been developed. The aim of this review is to summarize the current literatures on the GPC3 expression in human HCC, molecular mechanisms of GPC3 regulation and antibodies targeting GPC3.
- Published
- 2020